

Patricia Forgez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5767424/publications.pdf>

Version: 2024-02-01

15
papers

746
citations

687363

13
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

992
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Monoclonal Antibody Blockade of Long Fragment Neurotensin on Weight Loss, Behavior, and Metabolic Traits After High-Fat Diet Induced Obesity. <i>Frontiers in Endocrinology</i> , 2021, 12, 739287.	3.5	6
2	Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. <i>Cancer Letters</i> , 2019, 464, 5-14.	7.2	148
3	Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. <i>Cancer Letters</i> , 2019, 444, 147-161.	7.2	13
4	Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib. <i>Cancer Letters</i> , 2017, 388, 73-84.	7.2	27
5	Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 521-530.	2.8	10
6	Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6516-6528.	7.0	18
7	Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. <i>Oncotarget</i> , 2014, 5, 8235-8251.	1.8	35
8	Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. <i>Oncotarget</i> , 2014, 5, 8252-8269.	1.8	49
9	Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. <i>Frontiers in Endocrinology</i> , 2012, 3, 184.	3.5	90
10	The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. <i>Biochimie</i> , 2011, 93, 1369-1378.	2.6	81
11	Neurotensin Receptor 1 Determines the Outcome of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4401-4410.	7.0	94
12	Neurotensin receptor 1 gene activation by the Tcf/β2-catenin pathway is an early event in human colonic adenomas. <i>Carcinogenesis</i> , 2006, 27, 708-716.	2.8	63
13	Receptor Trafficking via the Perinuclear Recycling Compartment Accompanied by Cell Division Is Necessary for Permanent Neurotensin Cell Sensitization and Leads to Chronic Mitogen-activated Protein Kinase Activation. <i>Journal of Biological Chemistry</i> , 2004, 279, 12636-12646.	3.4	32
14	Activation of Receptor Gene Transcription Is Required to Maintain Cell Sensitization after Agonist Exposure. <i>Journal of Biological Chemistry</i> , 1998, 273, 21634-21641.	3.4	26
15	Neurotensin Agonist Induces Differential Regulation of Neurotensin Receptor mRNA. <i>Journal of Biological Chemistry</i> , 1997, 272, 10087-10094.	3.4	53